Peptide Legal Status by State

Peptide legality in the United States is determined by a combination of federal FDA regulation and state pharmacy board rules. At the federal level, the FDA classifies peptides as drugs, dietary supplements, or cosmetic ingredients depending on their intended use. Only peptides with approved New Drug Applications (NDAs) can be marketed as drugs for specific conditions.

Compounding pharmacies play a crucial role in peptide access. Under the Drug Quality and Security Act (DQSA), compounding pharmacies can prepare customized peptide formulations using bulk drug substances — but only if those substances are not on the FDA's Category 2 withdrawal list. In 2024, the FDA moved several popular research peptides to Category 2, effectively ending their legal compounding.

State laws add another layer. Permissive states generally follow federal guidelines without adding restrictions, meaning compounding pharmacies operate freely for non-Category-2 peptides. Restrictive states impose additional requirements: stricter compounding oversight, enhanced testing, limits on telemedicine prescribing, or additional consumer protection rules that can limit access.

Important: This guide reflects the regulatory landscape as of 2026. Laws change frequently. Always verify current regulations with your state pharmacy board and consult a licensed healthcare provider before obtaining or using any peptide therapy.